XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$1,432.29+1.44%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
68/100
Positive
Score components
TickerWhale View
Lilly(Eli) & Company scores 68 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Sentiment Signal
What to watch
- Valuation
- Risk
Quality & growth
30%100Strong
- Revenue growth 49.6%
- EPS growth 94.8%
Valuation
25%7Weak
- P/E 47.9
- EV/Sales 16.6
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
#9 by market cap in our coverage · ~50,000 employees · Listed 1970-07-09 · www.lilly.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#13 / 139sector rank by TickerWhale Score
TickerWhale Score 68 vs sector average 54.6 (+13.4)
Revenue growth (industry)Top 9%
Gross margin (industry)Top 9%
Return on equity (industry)Top 20%
P/E (industry)Pricier than 70%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
98/100Strong vs universe
Ranks 98th of 100 covered names on our technical composite — the composite itself scores 87/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale rates LLY's technical setup strong — 98th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+29.8%
- vs 50-day+17.0%
Momentum
Mixed
- RSI (14)70 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength46· trending
- MACD (12,26,9)buy(histogram 5.568)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)47.9
- P/S (TTM)16.1
- P/B37.8
- EV/EBITDA—
- EV/Sales16.6
- PEG—
Profitability & returns
- Gross margin83.4%
- Net margin33.5%
- ROE82.1%
- Debt/Equity1.62
Growth
- Revenue growth (YoY)49.6%
- EPS growth (YoY)94.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $1.28T
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B |
| Gross profit | $54.1B | $36.6B | $27.0B |
| Operating income | $26.3B | $12.9B | $6.5B |
| Net income | $20.6B | $10.6B | $5.2B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 |
| Free cash flow | $9.0B | $3.8B | $792M |
| Cash | $7.3B | $3.3B | $2.8B |
| Total debt | $42.5B | $33.6B | $25.2B |
| Equity | $26.5B | $14.3B | $10.8B |
| Net debt | $35.2B | $30.4B | $22.4B |
| Debt / equity | 1.60 | 2.36 | 2.34 |
| Liabilities / assets | 0.76 | 0.82 | 0.83 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLYCurrentLilly(Eli) & Company | 68 | 87 | 47.9 | — | 37.8 | 16.6 | $1,432.29 | +1.44% | +49.6% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.